Systematic Review
. 2021 May; 26(8):.
doi: 10.3390/molecules26082201.

The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers

Virginia Liberini 1 Riccardo Laudicella 2 Martina Capozza 3 Martin W Huellner 4 Irene A Burger 4 Sergio Baldari 2 Enzo Terreno 3 Désirée Deandreis 1 
Affiliations
  • PMID: 33920423
  •     163 References
  •     6 citations

Abstract

Immunotherapy is an effective therapeutic option for several cancers. In the last years, the introduction of checkpoint inhibitors (ICIs) has shifted the therapeutic landscape in oncology and improved patient prognosis in a variety of neoplastic diseases. However, to date, the selection of the best patients eligible for these therapies, as well as the response assessment is still challenging. Patients are mainly stratified using an immunohistochemical analysis of the expression of antigens on biopsy specimens, such as PD-L1 and PD-1, on tumor cells, on peritumoral immune cells and/or in the tumor microenvironment (TME). Recently, the use and development of imaging biomarkers able to assess in-vivo cancer-related processes are becoming more important. Today, positron emission tomography (PET) with 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) is used routinely to evaluate tumor metabolism, and also to predict and monitor response to immunotherapy. Although highly sensitive, FDG-PET in general is rather unspecific. Novel radiopharmaceuticals (immuno-PET radiotracers), able to identify specific immune system targets, are under investigation in pre-clinical and clinical settings to better highlight all the mechanisms involved in immunotherapy. In this review, we will provide an overview of the main new immuno-PET radiotracers in development. We will also review the main players (immune cells, tumor cells and molecular targets) involved in immunotherapy. Furthermore, we report current applications and the evidence of using [18F]FDG PET in immunotherapy, including the use of artificial intelligence (AI).

Keywords: AI; CAR-T cells; PD-1; PD-L1; deep learning; immune PET; immune checkpoint inhibitors; immune checkpoint radiolabeled antibodies; immunotherapy; radiomics.

CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Marina Martinez, Edmund Kyung Moon.
Front Immunol, 2019 Feb 26; 10. PMID: 30804938    Free PMC article.
Highly Cited. Review.
One-step radiosynthesis and initial evaluation of a small molecule PET tracer for PD-L1 imaging.
Yinxing Miao, Gaochao Lv, +3 authors, Jianguo Lin.
Bioorg Med Chem Lett, 2020 Sep 27; 30(24). PMID: 32979488
Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy.
Maciej Kujawski, Lin Li, +10 authors, John E Shively.
BMC Cancer, 2019 Sep 07; 19(1). PMID: 31488104    Free PMC article.
Noninvasive Imaging of Cancer Immunotherapy.
Omar Abousaway, Taha Rakhshandehroo, +2 authors, Mohammad Rashidian.
Nanotheranostics, 2021 Jan 05; 5(1). PMID: 33391977    Free PMC article.
Review.
Value of 18F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers.
Kyoichi Kaira, Ichiei Kuji, Hiroshi Kagamu.
Cancer Imaging, 2021 Jan 15; 21(1). PMID: 33441183    Free PMC article.
Review.
Immuno-PET of Murine T Cell Reconstitution Postadoptive Stem Cell Transplantation Using Anti-CD4 and Anti-CD8 Cys-Diabodies.
Richard Tavaré, Melissa N McCracken, +4 authors, Anna M Wu.
J Nucl Med, 2015 May 09; 56(8). PMID: 25952734    Free PMC article.
Natural killer cell adoptive immunotherapy: Coming of age.
Letícia Baggio, Álvaro Macedo Laureano, Lucia Mariano da Rocha Silla, Dean Anthony Lee.
Clin Immunol, 2016 Feb 18; 177. PMID: 26883680
Review.
Regulatory T cells: mechanisms of differentiation and function.
Steven Z Josefowicz, Li-Fan Lu, Alexander Y Rudensky.
Annu Rev Immunol, 2012 Jan 10; 30. PMID: 22224781    Free PMC article.
Highly Cited. Review.
N-(4-18F-fluorobenzoyl)interleukin-2 for PET of human-activated T lymphocytes.
Valentina Di Gialleonardo, Alberto Signore, +2 authors, Erik F J De Vries.
J Nucl Med, 2012 Apr 14; 53(5). PMID: 22499614
Topography of cancer-associated immune cells in human solid tumors.
Jakob Nikolas Kather, Meggy Suarez-Carmona, +17 authors, Niels Halama.
Elife, 2018 Sep 05; 7. PMID: 30179157    Free PMC article.
Highly Cited.
Antibody and fragment-based PET imaging of CTLA-4+ T-cells in humanized mouse models.
Emily B Ehlerding, Hye Jin Lee, +6 authors, Weibo Cai.
Am J Cancer Res, 2019 Feb 14; 9(1). PMID: 30755811    Free PMC article.
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia.
N Engl J Med, 2016 Mar 11; 374(10). PMID: 26962747
Skin cancer: T-VEC oncolytic viral therapy shows promise in melanoma.
David Killock.
Nat Rev Clin Oncol, 2015 Jun 17; 12(8). PMID: 26077044
Assessing immune organs on 18F-FDG PET/CT imaging for therapy monitoring of immune checkpoint inhibitors: inter-observer variability, prognostic value and evolution during the treatment course of melanoma patients.
Kevin Prigent, Charline Lasnon, +7 authors, Nicolas Aide.
Eur J Nucl Med Mol Imaging, 2021 Jan 13; 48(8). PMID: 33432374
In Vivo Tracking of Adoptively Transferred Natural Killer Cells in Rhesus Macaques Using 89Zirconium-Oxine Cell Labeling and PET Imaging.
Noriko Sato, Kate Stringaris, +5 authors, Richard W Childs.
Clin Cancer Res, 2020 Feb 09; 26(11). PMID: 32034075    Free PMC article.
Bispecific T-cell engaging antibodies for cancer therapy.
Patrick A Baeuerle, Carsten Reinhardt.
Cancer Res, 2009 Jun 11; 69(12). PMID: 19509221
Highly Cited. Review.
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Robert H I Andtbacka, Howard L Kaufman, +26 authors, Robert S Coffin.
J Clin Oncol, 2015 May 28; 33(25). PMID: 26014293
Highly Cited.
Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response.
Benjamin M Larimer, Eric Wehrenberg-Klee, +5 authors, Umar Mahmood.
Cancer Res, 2017 May 04; 77(9). PMID: 28461564    Free PMC article.
Highly Cited.
PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
Harriet M Kluger, Christopher R Zito, +9 authors, Lucia B Jilaveanu.
Clin Cancer Res, 2017 Feb 23; 23(15). PMID: 28223273    Free PMC article.
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.
David L Porter, Bruce L Levine, +2 authors, Carl H June.
N Engl J Med, 2011 Aug 13; 365(8). PMID: 21830940    Free PMC article.
Highly Cited.
Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics.
Romain-David Seban, John S Nemer, +13 authors, Laurent Dercle.
Eur J Nucl Med Mol Imaging, 2019 Jul 28; 46(11). PMID: 31346755
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy.
F Stephen Hodi, Marcus Ballinger, +13 authors, Jedd D Wolchok.
J Clin Oncol, 2018 Jan 18; 36(9). PMID: 29341833
Highly Cited.
Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.
Y Kawakami, S Eliyahu, +7 authors, S A Rosenberg.
Proc Natl Acad Sci U S A, 1994 Jul 05; 91(14). PMID: 8022805    Free PMC article.
Highly Cited.
Tapping CD4 T cells for cancer immunotherapy: the choice of personalized genomics.
Maurizio Zanetti.
J Immunol, 2015 Feb 25; 194(5). PMID: 25710958
Review.
89Zr radiochemistry for positron emission tomography.
Gregory W Severin, Jonathan W Engle, Todd E Barnhart, R Jerry Nickles.
Med Chem, 2011 Jun 30; 7(5). PMID: 21711221    Free PMC article.
Review.
The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis.
M J M Gooden, G H de Bock, +2 authors, H W Nijman.
Br J Cancer, 2011 Jun 02; 105(1). PMID: 21629244    Free PMC article.
Highly Cited. Systematic Review.
Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells.
Mohammad Rashidian, Jessica R Ingram, +11 authors, Hidde L Ploegh.
J Exp Med, 2017 Jul 02; 214(8). PMID: 28666979    Free PMC article.
Highly Cited.
Site-Specific Immuno-PET Tracer to Image PD-L1.
Haley L Wissler, Emily B Ehlerding, +11 authors, Rongsheng E Wang.
Mol Pharm, 2019 Mar 16; 16(5). PMID: 30875232    Free PMC article.
Imaging preclinical tumour models: improving translational power.
Marion de Jong, Jeroen Essers, Wytske M van Weerden.
Nat Rev Cancer, 2014 Jun 20; 14(7). PMID: 24943811
Highly Cited. Review.
Immuno-PET Imaging of 89Zr Labeled Anti-PD-L1 Domain Antibody.
Dan Li, Siyuan Cheng, +4 authors, Xiaohua Zhu.
Mol Pharm, 2018 Mar 06; 15(4). PMID: 29502426
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
Interleukin-2 receptor signaling: at the interface between tolerance and immunity.
Thomas R Malek, Iris Castro.
Immunity, 2010 Aug 25; 33(2). PMID: 20732639    Free PMC article.
Highly Cited. Review.
Tumor-infiltrating dendritic cells in cancer pathogenesis.
Jo Marie Tran Janco, Purushottam Lamichhane, Lavakumar Karyampudi, Keith L Knutson.
J Immunol, 2015 Mar 22; 194(7). PMID: 25795789    Free PMC article.
Highly Cited. Review.
Spatiotemporal PET Imaging Reveals Differences in CAR-T Tumor Retention in Triple-Negative Breast Cancer Models.
Alessia Volpe, Cameron Lang, +7 authors, Gilbert O Fruhwirth.
Mol Ther, 2020 Jul 10; 28(10). PMID: 32645298    Free PMC article.
Roles of the immune system in cancer: from tumor initiation to metastatic progression.
Hugo Gonzalez, Catharina Hagerling, Zena Werb.
Genes Dev, 2018 Oct 03; 32(19-20). PMID: 30275043    Free PMC article.
Highly Cited. Review.
Clinical-grade N-(4-[18F]fluorobenzoyl)-interleukin-2 for PET imaging of activated T-cells in humans.
Elly L van der Veen, Inês F Antunes, +8 authors, Erik F J de Vries.
EJNMMI Radiopharm Chem, 2019 Oct 30; 4(1). PMID: 31659562    Free PMC article.
Mechanisms and clinical implications of tumor heterogeneity and convergence on recurrent phenotypes.
Jasmine A McQuerry, Jeffrey T Chang, +2 authors, Andrea H Bild.
J Mol Med (Berl), 2017 Sep 06; 95(11). PMID: 28871446    Free PMC article.
Review.
PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody.
Gaochao Lv, Xiaorong Sun, +6 authors, Jianguo Lin.
J Nucl Med, 2019 Jun 30; 61(1). PMID: 31253743    Free PMC article.
Recent advances of bispecific antibodies in solid tumors.
Shengnan Yu, Anping Li, +6 authors, Kongming Wu.
J Hematol Oncol, 2017 Sep 22; 10(1). PMID: 28931402    Free PMC article.
Highly Cited. Review.
[18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab.
Damijan Valentinuzzi, Martina Vrankar, +9 authors, Robert Jeraj.
Radiol Oncol, 2020 Jul 30; 54(3). PMID: 32726293    Free PMC article.
The therapeutic potential of targeting tryptophan catabolism in cancer.
Christiane A Opitz, Luis F Somarribas Patterson, +4 authors, Saskia Trump.
Br J Cancer, 2019 Dec 11; 122(1). PMID: 31819194    Free PMC article.
Review.
An 89Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor.
Christian A Mason, Susanne Kossatz, +7 authors, Thomas Reiner.
J Nucl Med, 2019 Aug 20; 61(3). PMID: 31420495    Free PMC article.
18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival.
Giulia Polverari, Francesco Ceci, +11 authors, Désirée Deandreis.
Cancers (Basel), 2020 May 10; 12(5). PMID: 32380754    Free PMC article.
Targeted agents and immunotherapies: optimizing outcomes in melanoma.
Jason J Luke, Keith T Flaherty, Antoni Ribas, Georgina V Long.
Nat Rev Clin Oncol, 2017 Apr 05; 14(8). PMID: 28374786
Highly Cited. Review.
Tumour-associated macrophages as treatment targets in oncology.
Alberto Mantovani, Federica Marchesi, +2 authors, Paola Allavena.
Nat Rev Clin Oncol, 2017 Jan 25; 14(7). PMID: 28117416    Free PMC article.
Highly Cited. Review.
Simultaneous in vivo PET/MRI using fluorine-18 labeled Fe3O4@Al(OH)3 nanoparticles: comparison of nanoparticle and nanoparticle-labeled stem cell distribution.
Sarah Belderbos, Manuel Antonio González-Gómez, +8 authors, Uwe Himmelreich.
EJNMMI Res, 2020 Jul 02; 10(1). PMID: 32607918    Free PMC article.
Artificial Neural Networks in Cardiovascular Diseases and its Potential for Clinical Application in Molecular Imaging.
Riccardo Laudicella, Albert Comelli, +9 authors, Pierpaolo Alongi.
Curr Radiopharm, 2020 Jun 23; 14(3). PMID: 32564769
Review.
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
Marco Gerlinger, Andrew J Rowan, +28 authors, Charles Swanton.
N Engl J Med, 2012 Mar 09; 366(10). PMID: 22397650    Free PMC article.
Highly Cited.
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, +27 authors, Mario Sznol.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658127    Free PMC article.
Highly Cited.
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.
Renier J Brentjens, Marco L Davila, +22 authors, Michel Sadelain.
Sci Transl Med, 2013 Mar 22; 5(177). PMID: 23515080    Free PMC article.
Highly Cited.
Imaging PD-L1 Expression with ImmunoPET.
Charles Truillet, Hsueh Ling J Oh, +19 authors, Michael J Evans.
Bioconjug Chem, 2017 Nov 11; 29(1). PMID: 29125731    Free PMC article.
Value of pre-therapy 18F-FDG PET/CT radiomics in predicting EGFR mutation status in patients with non-small cell lung cancer.
Jianyuan Zhang, Xinming Zhao, +6 authors, Jingya Han.
Eur J Nucl Med Mol Imaging, 2019 Nov 16; 47(5). PMID: 31728587
Regulation and Function of the PD-L1 Checkpoint.
Chong Sun, Riccardo Mezzadra, Ton N Schumacher.
Immunity, 2018 Mar 22; 48(3). PMID: 29562194    Free PMC article.
Highly Cited. Review.
Adoptive cell transfer: a clinical path to effective cancer immunotherapy.
Steven A Rosenberg, Nicholas P Restifo, +2 authors, Mark E Dudley.
Nat Rev Cancer, 2008 Mar 21; 8(4). PMID: 18354418    Free PMC article.
Highly Cited. Review.
CAR T cells in solid tumors: challenges and opportunities.
Faroogh Marofi, Roza Motavalli, +12 authors, Farhad Motavalli Khiavi.
Stem Cell Res Ther, 2021 Jan 27; 12(1). PMID: 33494834    Free PMC article.
Review.
Therapeutic Potential of Mesenchymal Stem Cells for Cancer Therapy.
Abdelkrim Hmadcha, Alejandro Martin-Montalvo, +2 authors, Vivian Capilla-Gonzalez.
Front Bioeng Biotechnol, 2020 Mar 03; 8. PMID: 32117924    Free PMC article.
Review.
Development of [18F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide.
Wojciech G Lesniak, Ronnie C Mease, +7 authors, Sridhar Nimmagadda.
Mol Imaging, 2019 Jun 13; 18. PMID: 31187691    Free PMC article.
Synthesis of 2'-deoxy-2'-[18F]fluoro-9-β-D-arabinofuranosylguanine: a novel agent for imaging T-cell activation with PET.
Mohammad Namavari, Ya-Fang Chang, +3 authors, Sanjiv Sam Gambhir.
Mol Imaging Biol, 2010 Sep 15; 13(5). PMID: 20838911
Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy.
Shabnam Shalapour, Joan Font-Burgada, +13 authors, Michael Karin.
Nature, 2015 Apr 30; 521(7550). PMID: 25924065    Free PMC article.
Highly Cited.
PD-L1 detection using 89Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response.
Joseph Vento, Aditi Mulgaonkar, +11 authors, James Brugarolas.
J Immunother Cancer, 2019 Jun 04; 7(1). PMID: 31155004    Free PMC article.
Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade.
Mohammad Rashidian, Martin W LaFleur, +13 authors, Hidde L Ploegh.
Proc Natl Acad Sci U S A, 2019 Aug 04; 116(34). PMID: 31375632    Free PMC article.
Preclinical ImmunoPET Imaging of Glioblastoma-Infiltrating Myeloid Cells Using Zirconium-89 Labeled Anti-CD11b Antibody.
Shubhanchi Nigam, Lauren McCarl, +6 authors, W Barry Edwards.
Mol Imaging Biol, 2019 Sep 19; 22(3). PMID: 31529407    Free PMC article.
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.
Bruce D Cheson, Stephen Ansell, +6 authors, Philippe Armand.
Blood, 2016 Aug 31; 128(21). PMID: 27574190
Highly Cited. Review.
18F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma.
Kimiteru Ito, Rebecca Teng, +7 authors, Wolfgang A Weber.
J Nucl Med, 2018 Nov 11; 60(3). PMID: 30413661    Free PMC article.
The PET-Tracer 89Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment.
Christoph M Griessinger, Tove Olafsen, +26 authors, Jean J L Tessier.
Cancer Res, 2020 May 16; 80(13). PMID: 32409308
Radiosynthesis and preclinical PET evaluation of 89Zr-nivolumab (BMS-936558) in healthy non-human primates.
Erin L Cole, Joonyoung Kim, +8 authors, Samuel Bonacorsi.
Bioorg Med Chem, 2017 Aug 15; 25(20). PMID: 28803798
Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria.
M Tazdait, L Mezquita, +10 authors, C Caramella.
Eur J Cancer, 2017 Nov 29; 88. PMID: 29182990
Highly Cited.
Imaging of cell-based therapy using 89Zr-oxine ex vivo cell labeling for positron emission tomography.
Yutaka Kurebayashi, Peter L Choyke, Noriko Sato.
Nanotheranostics, 2021 Jan 05; 5(1). PMID: 33391973    Free PMC article.
Review.
Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy.
Mengxin Xu, Yuxiang Han, +6 authors, Zhibo Liu.
Mol Pharm, 2018 Aug 23; 15(10). PMID: 30133286
The immune contexture in cancer prognosis and treatment.
Wolf H Fridman, Laurence Zitvogel, Catherine Sautès-Fridman, Guido Kroemer.
Nat Rev Clin Oncol, 2017 Jul 26; 14(12). PMID: 28741618
Highly Cited. Review.
Examining Immunotherapy Response Using Multiple Radiotracers.
Julian L Goggi, Siddesh V Hartimath, +15 authors, Edward G Robins.
Mol Imaging Biol, 2020 Feb 02; 22(4). PMID: 32006204
Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer.
A N Niemeijer, D Leung, +20 authors, A J de Langen.
Nat Commun, 2018 Nov 09; 9(1). PMID: 30405135    Free PMC article.
Highly Cited.
Baseline 18F-FDG PET radiomic features as predictors of 2-year event-free survival in diffuse large B cell lymphomas treated with immunochemotherapy.
Nicolas Aide, Christophe Fruchart, +2 authors, Charline Lasnon.
Eur Radiol, 2020 Apr 06; 30(8). PMID: 32248365
Noninvasive monitoring of cancer therapy induced activated T cells using [18F]FB-IL-2 PET imaging.
S V Hartimath, O Draghiciu, +5 authors, E F J de Vries.
Oncoimmunology, 2017 Feb 16; 6(1). PMID: 28197364    Free PMC article.
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.
Spencer C Wei, Colm R Duffy, James P Allison.
Cancer Discov, 2018 Aug 18; 8(9). PMID: 30115704
Highly Cited. Review.
Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma.
Changhee Park, Kwon Joong Na, +14 authors, Dae Seog Heo.
Theranostics, 2020 Sep 16; 10(23). PMID: 32929383    Free PMC article.
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy.
Antje Tunger, Ulrich Sommer, +7 authors, Marc Schmitz.
J Clin Med, 2019 Sep 29; 8(10). PMID: 31557787    Free PMC article.
Review.
Imaging CAR T cell therapy with PSMA-targeted positron emission tomography.
Il Minn, David J Huss, +9 authors, Martin G Pomper.
Sci Adv, 2019 Jul 10; 5(7). PMID: 31281894    Free PMC article.
Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer.
Khalid I Al-Shibli, Tom Donnem, +3 authors, Lill-Tove Busund.
Clin Cancer Res, 2008 Aug 14; 14(16). PMID: 18698040
Highly Cited.
Reassessing Patterns of Response to Immunotherapy with PET: From Morphology to Metabolism.
Larissa B Costa, Marcelo A Queiroz, +7 authors, Carlos A Buchpiguel.
Radiographics, 2020 Dec 05; 41(1). PMID: 33275541
Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma.
Khun Visith Keu, Timothy H Witney, +14 authors, Sanjiv S Gambhir.
Sci Transl Med, 2017 Jan 20; 9(373). PMID: 28100832    Free PMC article.
Highly Cited.
Prognostic Value of Maximum Standardized Uptake Value in 68Ga-Somatostatin Receptor Positron Emission Tomography for Neuroendocrine Tumors: A Systematic Review and Meta-analysis.
Dong Yun Lee, Yong-Il Kim.
Clin Nucl Med, 2019 Jul 10; 44(10). PMID: 31283601
Systematic Review.
Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody.
Camilla Christensen, Lotte K Kristensen, +2 authors, Andreas Kjaer.
Eur J Nucl Med Mol Imaging, 2019 Dec 29; 47(5). PMID: 31883023    Free PMC article.
CTLA-4: a moving target in immunotherapy.
Behzad Rowshanravan, Neil Halliday, David M Sansom.
Blood, 2017 Nov 10; 131(1). PMID: 29118008    Free PMC article.
Highly Cited. Review.
Neutrophil Heterogeneity in Cancer: From Biology to Therapies.
Pacôme Lecot, Matthieu Sarabi, +5 authors, Marie-Cécile Michallet.
Front Immunol, 2019 Oct 17; 10. PMID: 31616408    Free PMC article.
Review.
Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes.
Arutselvan Natarajan, Aaron T Mayer, +3 authors, Sanjiv S Gambhir.
Bioconjug Chem, 2015 Aug 27; 26(10). PMID: 26307602
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications.
Yuanyuan Zhang, Zemin Zhang.
Cell Mol Immunol, 2020 Jul 03; 17(8). PMID: 32612154    Free PMC article.
Review.
Assessing EGFR gene mutation status in non-small cell lung cancer with imaging features from PET/CT.
Mengmeng Jiang, Yiqian Zhang, +7 authors, Mengsu Zeng.
Nucl Med Commun, 2019 Jul 11; 40(8). PMID: 31290849
Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer.
Anders Josefsson, Jessie R Nedrow, +5 authors, George Sgouros.
Cancer Res, 2015 Nov 12; 76(2). PMID: 26554829    Free PMC article.
Highly Cited.
Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab.
Hoda Anwar, Christos Sachpekidis, +4 authors, Antonia Dimitrakopoulou-Strauss.
Eur J Nucl Med Mol Imaging, 2017 Nov 11; 45(3). PMID: 29124281
Enhancing Anti-PD-1/PD-L1 Immune Checkpoint Inhibitory Cancer Therapy by CD276-Targeted Photodynamic Ablation of Tumor Cells and Tumor Vasculature.
Rui Bao, Yanpu Wang, +8 authors, Zhaofei Liu.
Mol Pharm, 2018 Nov 20; 16(1). PMID: 30452269
18F-FDG PET/CT metabolic tumor parameters and radiomics features in aggressive non-Hodgkin's lymphoma as predictors of treatment outcome and survival.
Aatif Parvez, Noam Tau, +2 authors, Ur Metser.
Ann Nucl Med, 2018 May 14; 32(6). PMID: 29754276
Assessing PD-L1 Expression Level by Radiomic Features From PET/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result.
Mengmeng Jiang, Dazhen Sun, +4 authors, Xiuzhong Yao.
Acad Radiol, 2019 May 31; 27(2). PMID: 31147234
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.
P van der Bruggen, C Traversari, +5 authors, T Boon.
Science, 1991 Dec 13; 254(5038). PMID: 1840703
Highly Cited.
Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy.
Filippo Galli, Jesus Vera Aguilera, +3 authors, Alberto Signore.
J Exp Clin Cancer Res, 2020 May 20; 39(1). PMID: 32423420    Free PMC article.
Review.
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes.
Alberto Mantovani, Silvano Sozzani, +2 authors, Antonio Sica.
Trends Immunol, 2002 Oct 29; 23(11). PMID: 12401408
Highly Cited. Review.
Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non-Small Cell Lung Cancer.
Lucian Beer, Maximilian Hochmair, +10 authors, Helmut Prosch.
Clin Nucl Med, 2019 Apr 26; 44(7). PMID: 31021918
89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer.
Christopher G England, Dawei Jiang, +7 authors, Weibo Cai.
Eur J Nucl Med Mol Imaging, 2017 Aug 20; 45(1). PMID: 28821924    Free PMC article.
Introduction to Radiomics.
Marius E Mayerhoefer, Andrzej Materka, +4 authors, Gary Cook.
J Nucl Med, 2020 Feb 16; 61(4). PMID: 32060219
Review.
ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28.
A Hutloff, A M Dittrich, +4 authors, R A Kroczek.
Nature, 1999 Feb 04; 397(6716). PMID: 9930702
Highly Cited.
CD4+ and CD8a+ PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models.
Lotte K Kristensen, Camilla Fröhlich, +8 authors, Andreas Kjaer.
Theranostics, 2019 Nov 23; 9(26). PMID: 31754392    Free PMC article.
Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4+ tumor infiltrating lymphocytes and their in situ localization.
Luca Mastracci, Vincenzo Fontana, +13 authors, Maria Pia Pistillo.
Cancer Immunol Immunother, 2020 Feb 07; 69(4). PMID: 32025849
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.
Jedd D Wolchok, Axel Hoos, +9 authors, F Stephen Hodi.
Clin Cancer Res, 2009 Nov 26; 15(23). PMID: 19934295
Highly Cited.
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.
Alessandro Liberati, Douglas G Altman, +7 authors, David Moher.
J Clin Epidemiol, 2009 Jul 28; 62(10). PMID: 19631507
Highly Cited. Systematic Review.
In vivo characterization of PD-L1 expression in breast cancer by immuno-PET with 89Zr-labeled avelumab.
Miao Li, Emily B Ehlerding, +5 authors, Weibo Cai.
Am J Transl Res, 2020 Jun 09; 12(5). PMID: 32509182    Free PMC article.
Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma.
Masahiro Kikuchi, David A Clump, +6 authors, Robert L Ferris.
Oncoimmunology, 2017 Aug 16; 6(7). PMID: 28811971    Free PMC article.
Tertiary lymphoid structures improve immunotherapy and survival in melanoma.
Rita Cabrita, Martin Lauss, +22 authors, Göran Jönsson.
Nature, 2020 Jan 17; 577(7791). PMID: 31942071
Highly Cited.
Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis.
Yutian Zou, Xiaoqian Hu, +5 authors, Xiaoming Xie.
EBioMedicine, 2020 Dec 15; 63. PMID: 33310681    Free PMC article.
Systematic Review.
ICOS Is an Indicator of T-cell-Mediated Response to Cancer Immunotherapy.
Zunyu Xiao, Aaron T Mayer, Tomomi W Nobashi, Sanjiv S Gambhir.
Cancer Res, 2020 Mar 12; 80(14). PMID: 32156777
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
Lesley Seymour, Jan Bogaerts, +16 authors, RECIST working group.
Lancet Oncol, 2017 Mar 09; 18(3). PMID: 28271869    Free PMC article.
Highly Cited. Review.
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis.
Flora Mulkey, Marc R Theoret, +2 authors, Rajeshwari Sridhara.
J Immunother Cancer, 2020 Feb 29; 8(1). PMID: 32107275    Free PMC article.
Novel (89)Zr cell labeling approach for PET-based cell trafficking studies.
Aditya Bansal, Mukesh K Pandey, +5 authors, Timothy R DeGrado.
EJNMMI Res, 2015 Apr 29; 5. PMID: 25918673    Free PMC article.
Rapid PD-L1 detection in tumors with PET using a highly specific peptide.
Samit Chatterjee, Wojciech G Lesniak, +8 authors, Sridhar Nimmagadda.
Biochem Biophys Res Commun, 2016 Dec 28; 483(1). PMID: 28025143    Free PMC article.
Monitoring the Response of PD-L1 Expression to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonsmall-Cell Lung Cancer Xenografts by Immuno-PET Imaging.
Dan Li, Sijuan Zou, +3 authors, Xiaohua Zhu.
Mol Pharm, 2019 Jul 10; 16(8). PMID: 31283253
Peptide-based PET quantifies target engagement of PD-L1 therapeutics.
Dhiraj Kumar, Ala Lisok, +15 authors, Sridhar Nimmagadda.
J Clin Invest, 2018 Nov 21; 129(2). PMID: 30457978    Free PMC article.
A guide to cancer immunotherapy: from T cell basic science to clinical practice.
Alex D Waldman, Jill M Fritz, Michael J Lenardo.
Nat Rev Immunol, 2020 May 21; 20(11). PMID: 32433532    Free PMC article.
Review.
Tumour-associated microglia/macrophages predict poor prognosis in high-grade gliomas and correlate with an aggressive tumour subtype.
M D Sørensen, R H Dahlrot, +2 authors, B W Kristensen.
Neuropathol Appl Neurobiol, 2017 Aug 03; 44(2). PMID: 28767130
The value of 18F-FDG PET/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis.
Narjess Ayati, Ramin Sadeghi, +3 authors, Andrew M Scott.
Eur J Nucl Med Mol Imaging, 2020 Jul 31; 48(2). PMID: 32728798
Systematic Review.
Development and Evaluation of Interleukin-2-Derived Radiotracers for PET Imaging of T Cells in Mice.
Elly L van der Veen, Frans V Suurs, +7 authors, Inês F Antunes.
J Nucl Med, 2020 Mar 01; 61(9). PMID: 32111688    Free PMC article.
The Importance of Biopsy in the Era of Molecular Medicine.
Etay Ziv, Jeremy C Durack, Stephen B Solomon.
Cancer J, 2016 Nov 22; 22(6). PMID: 27870685    Free PMC article.
Review.
Predictive Power of a Radiomic Signature Based on 18F-FDG PET/CT Images for EGFR Mutational Status in NSCLC.
Xiaofeng Li, Guotao Yin, +6 authors, Wengui Xu.
Front Oncol, 2019 Nov 05; 9. PMID: 31681597    Free PMC article.
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence.
Raju K Vaddepally, Prakash Kharel, +2 authors, Abhinav B Chandra.
Cancers (Basel), 2020 Apr 05; 12(3). PMID: 32245016    Free PMC article.
Review.
89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer.
Frederike Bensch, Elly L van der Veen, +18 authors, Elisabeth G E de Vries.
Nat Med, 2018 Nov 28; 24(12). PMID: 30478423
Highly Cited.
Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.
Aaron T Mayer, Arutselvan Natarajan, +5 authors, Sanjiv S Gambhir.
J Nucl Med, 2016 Dec 17; 58(4). PMID: 27980047    Free PMC article.
Radiomics of 18F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy.
Wei Mu, Ilke Tunali, +3 authors, Robert J Gillies.
Eur J Nucl Med Mol Imaging, 2019 Dec 07; 47(5). PMID: 31807885    Free PMC article.
ImmunoPET Imaging of Murine CD4+ T Cells Using Anti-CD4 Cys-Diabody: Effects of Protein Dose on T Cell Function and Imaging.
Amanda C Freise, Kirstin A Zettlitz, +3 authors, Anna M Wu.
Mol Imaging Biol, 2016 Dec 15; 19(4). PMID: 27966069    Free PMC article.
PET of Adoptively Transferred Chimeric Antigen Receptor T Cells with 89Zr-Oxine.
Michael R Weist, Renate Starr, +10 authors, John E Shively.
J Nucl Med, 2018 May 08; 59(10). PMID: 29728514    Free PMC article.
FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls.
Steve Y Cho, Daniel T Huff, Robert Jeraj, Mark R Albertini.
Semin Nucl Med, 2020 Oct 17; 50(6). PMID: 33059821    Free PMC article.
Review.
The blockade of immune checkpoints in cancer immunotherapy.
Drew M Pardoll.
Nat Rev Cancer, 2012 Mar 23; 12(4). PMID: 22437870    Free PMC article.
Highly Cited. Review.
Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition.
Lucas Basler, Hubert S Gabryś, +10 authors, Mitchell P Levesque.
Clin Cancer Res, 2020 Apr 08; 26(16). PMID: 32253232
Clinical molecular imaging with radiotracers: current status.
Michael M Graham.
Med Princ Pract, 2011 Dec 07; 21(3). PMID: 22142905
Review.
PET imaging of immune checkpoint proteins in oncology.
Alizée Bouleau, Vincent Lebon, Charles Truillet.
Pharmacol Ther, 2020 Dec 12; 222. PMID: 33307142
Review.
CD8+ T-Cell Density Imaging with 64Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols.
Jai Woong Seo, Richard Tavaré, +7 authors, Katherine W Ferrara.
Clin Cancer Res, 2018 Jul 04; 24(20). PMID: 29967252    Free PMC article.
Usefulness of gradient tree boosting for predicting histological subtype and EGFR mutation status of non-small cell lung cancer on 18F FDG-PET/CT.
Sho Koyasu, Mizuho Nishio, +2 authors, Kaori Togashi.
Ann Nucl Med, 2019 Oct 30; 34(1). PMID: 31659591
Tumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights.
Sandeep Kumar, Sunil Kumar Singh, Basabi Rana, Ajay Rana.
Drug Discov Today, 2021 Jan 16; 26(4). PMID: 33450394    Free PMC article.
Review.
First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting.
Neeta Pandit-Taskar, Michael A Postow, +18 authors, Jedd D Wolchok.
J Nucl Med, 2019 Oct 06; 61(4). PMID: 31586002    Free PMC article.
89Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs.
Elly L van der Veen, Danique Giesen, +3 authors, Marjolijn N Lub-de Hooge.
J Immunother Cancer, 2020 Oct 07; 8(2). PMID: 33020241    Free PMC article.
PET/CT Imaging of 89Zr-N-sucDf-Pembrolizumab in Healthy Cynomolgus Monkeys.
Wenping Li, Yuchuan Wang, +15 authors, Eric D Hostetler.
Mol Imaging Biol, 2020 Oct 27; 23(2). PMID: 33104972    Free PMC article.
Monitoring CD8a+ T Cell Responses to Radiotherapy and CTLA-4 Blockade Using [64Cu]NOTA-CD8a PET Imaging.
Lotte K Kristensen, Camilla Christensen, +3 authors, Andreas Kjaer.
Mol Imaging Biol, 2020 Feb 23; 22(4). PMID: 32086762    Free PMC article.
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Philip W Kantoff, Celestia S Higano, +11 authors, IMPACT Study Investigators.
N Engl J Med, 2010 Sep 08; 363(5). PMID: 20818862
Highly Cited.
Quantitative Imaging of Tumor-Associated Macrophages and Their Response to Therapy Using 64Cu-Labeled Macrin.
Hye-Yeong Kim, Ran Li, +8 authors, Miles A Miller.
ACS Nano, 2018 Dec 07; 12(12). PMID: 30508377    Free PMC article.
Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis.
Hyo Jung Park, Kyung Won Kim, +4 authors, Mizuki Nishino.
Radiology, 2020 Aug 05; 297(1). PMID: 32749204    Free PMC article.
Systematic Review.
Imaging of Activated T Cells as an Early Predictor of Immune Response to Anti-PD-1 Therapy.
Jelena Levi, Tina Lam, +10 authors, Henry VanBrocklin.
Cancer Res, 2019 May 09; 79(13). PMID: 31064845    Free PMC article.
CAR T-cells for cancer therapy.
Niaz Muhammad, Qinwen Mao, Haibin Xia.
Biotechnol Genet Eng Rev, 2018 Feb 13; 33(2). PMID: 29431047
Review.
Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 1: The Role of 18F-FDG PET/CT.
Amir Iravani, Rodney J Hicks.
J Nucl Med, 2020 May 24; 61(7). PMID: 32444375
Review.
Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo.
Richard Tavaré, Melissa N McCracken, +5 authors, Anna M Wu.
Proc Natl Acad Sci U S A, 2014 Jan 07; 111(3). PMID: 24390540    Free PMC article.
Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts.
Camilla Jandus, Gilles Bioley, +9 authors, Pedro Romero.
Cancer Res, 2009 Oct 08; 69(20). PMID: 19808957
In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1.
Daniel J Rubins, Xiangjun Meng, +16 authors, Jeffrey L Evelhoch.
Mol Imaging Biol, 2020 Oct 25; 23(2). PMID: 33098025
ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer.
Emily B Ehlerding, Christopher G England, +6 authors, Weibo Cai.
Mol Pharm, 2017 Apr 08; 14(5). PMID: 28388076    Free PMC article.
Quantitative CD3 PET Imaging Predicts Tumor Growth Response to Anti-CTLA-4 Therapy.
Benjamin M Larimer, Eric Wehrenberg-Klee, Alexander Caraballo, Umar Mahmood.
J Nucl Med, 2016 May 28; 57(10). PMID: 27230929    Free PMC article.
Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors.
Katerina T Xenaki, Sabrina Oliveira, Paul M P van Bergen En Henegouwen.
Front Immunol, 2017 Oct 28; 8. PMID: 29075266    Free PMC article.
Development of radiotracers for oncology--the interface with pharmacology.
Rohini Sharma, Eric Aboagye.
Br J Pharmacol, 2010 Dec 24; 163(8). PMID: 21175573    Free PMC article.
Review.
Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.
Greg M Thurber, Michael M Schmidt, K Dane Wittrup.
Adv Drug Deliv Rev, 2008 Jun 11; 60(12). PMID: 18541331    Free PMC article.
Highly Cited. Review.
PET Imaging of the Natural Killer Cell Activation Receptor NKp30.
Travis M Shaffer, Amin Aalipour, Christian M Schürch, Sanjiv S Gambhir.
J Nucl Med, 2020 Jun 14; 61(9). PMID: 32532927    Free PMC article.
Theoretic criteria for antibody penetration into solid tumors and micrometastases.
Greg M Thurber, Stefan C Zajic, K Dane Wittrup.
J Nucl Med, 2007 May 17; 48(6). PMID: 17504872
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
Omid Hamid, Caroline Robert, +23 authors, Antoni Ribas.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724846    Free PMC article.
Highly Cited.
A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR.
Claudia Arndt, Anja Feldmann, +16 authors, Michael Bachmann.
Oncoimmunology, 2019 Oct 28; 8(11). PMID: 31646084    Free PMC article.
Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients.
Norbert Meidenbauer, Joerg Marienhagen, +4 authors, Andreas Mackensen.
J Immunol, 2003 Feb 08; 170(4). PMID: 12574389
In vivo Imaging Technologies to Monitor the Immune System.
Claire E McCarthy, Jordan M White, Nerissa T Viola, Heather M Gibson.
Front Immunol, 2020 Jun 26; 11. PMID: 32582173    Free PMC article.
Review.
Peptide-Based 68Ga-PET Radiotracer for Imaging PD-L1 Expression in Cancer.
Ravindra A De Silva, Dhiraj Kumar, +7 authors, Sridhar Nimmagadda.
Mol Pharm, 2018 Jul 25; 15(9). PMID: 30037229    Free PMC article.
Next Generation Imaging Techniques to Define Immune Topographies in Solid Tumors.
Violena Pietrobon, Alessandra Cesano, Francesco Marincola, Jakob Nikolas Kather.
Front Immunol, 2021 Feb 16; 11. PMID: 33584676    Free PMC article.
Review.
Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor.
Sehhoon Park, Seunggyun Ha, +5 authors, Dae Seog Heo.
PLoS One, 2018 Feb 01; 13(1). PMID: 29385152    Free PMC article.
CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer.
Julie S Nielsen, Rob A Sahota, +4 authors, Brad H Nelson.
Clin Cancer Res, 2012 May 04; 18(12). PMID: 22553348
Highly Cited.
Targeting the Urokinase-Type Plasminogen Activator Receptor (uPAR) in Human Diseases With a View to Non-invasive Imaging and Therapeutic Intervention.
Julie Maja Leth, Michael Ploug.
Front Cell Dev Biol, 2021 Sep 08; 9. PMID: 34490277    Free PMC article.
Review.
NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images.
Virginia Liberini, Annapaola Mariniello, +7 authors, Désirée Deandreis.
Cancers (Basel), 2021 Sep 29; 13(18). PMID: 34572771    Free PMC article.
Review.
Immune Checkpoint Inhibitors in Advanced NSCLC: [18F]FDG PET/CT as a Troubleshooter in Treatment Response.
Cristina Ferrari, Giulia Santo, +5 authors, Giuseppe Rubini.
Diagnostics (Basel), 2021 Sep 29; 11(9). PMID: 34574022    Free PMC article.
Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma.
Virginia Liberini, Marco Rubatto, +11 authors, Désirée Deandreis.
J Clin Med, 2021 Nov 14; 10(21). PMID: 34768517    Free PMC article.
[68Ga]DOTATOC PET/CT Radiomics to Predict the Response in GEP-NETs Undergoing [177Lu]DOTATOC PRRT: The "Theragnomics" Concept.
Riccardo Laudicella, Albert Comelli, +14 authors, Sergio Baldari.
Cancers (Basel), 2022 Feb 26; 14(4). PMID: 35205733    Free PMC article.
Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review.
Michele Balma, Virginia Liberini, +15 authors, Désirée Deandreis.
Front Med (Lausanne), 2022 May 03; 9. PMID: 35492341    Free PMC article.
Systematic Review.